{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:40:51Z","timestamp":1785426051648,"version":"3.56.0"},"posted":{"date-parts":[[2024,10,6]]},"group-title":"Cancer Biology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["R00 CA148963"],"award-info":[{"award-number":["R00 CA148963"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01 CA244900"],"award-info":[{"award-number":["R01 CA244900"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["T32 CA009467"],"award-info":[{"award-number":["T32 CA009467"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["P20 GM121316"],"award-info":[{"award-number":["P20 GM121316"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Inversion of chromosome 16 [inv(16)] generates the fusion gene\n                  <jats:italic>CBFB::MYH11 (CM)<\/jats:italic>\n                  and is one of the most common chromosomal rearrangements in Acute Myeloid Leukemia (AML). Expression of\n                  <jats:italic>CM<\/jats:italic>\n                  is required for leukemia initiation. Patients with inv(16) at diagnosis invariably have the rearrangement at relapse, leading to the assumption that\n                  <jats:italic>CM<\/jats:italic>\n                  is also required after leukemic transformation. However, a role for\n                  <jats:italic>CM<\/jats:italic>\n                  in leukemia maintenance has yet to be shown experimentally. To address this, we used an inducible\n                  <jats:italic>CM<\/jats:italic>\n                  knockdown (KD) mouse model and found that decreased\n                  <jats:italic>CM<\/jats:italic>\n                  eliminated leukemia cells from the peripheral blood and spleen, but not the bone marrow, despite all populations exhibiting significantly decreased\n                  <jats:italic>CM<\/jats:italic>\n                  mRNA and protein. The surviving\n                  <jats:italic>CM<\/jats:italic>\n                  KD cells in the bone marrow showed decreased apoptosis and proliferation, and increased expression of autophagy related genes. Surprisingly, with prolonged KD of\n                  <jats:italic>CM<\/jats:italic>\n                  , \u223c40% of mice re-established disease despite maintaining decreased\n                  <jats:italic>CM<\/jats:italic>\n                  . Our work indicates that\n                  <jats:italic>CM<\/jats:italic>\n                  is required for leukemia survival in the spleen and peripheral blood, but in the bone marrow\n                  <jats:italic>CM<\/jats:italic>\n                  KD leukemia cells can survive and re-establish disease independent of the fusion protein. These findings imply that targeting\n                  <jats:italic>CM<\/jats:italic>\n                  alone has potential to reduce leukemic burden but not cure the disease.\n                <\/jats:p>","DOI":"10.1101\/2024.10.06.616896","type":"posted-content","created":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T23:00:11Z","timestamp":1728255611000},"source":"Crossref","is-referenced-by-count":0,"title":["Tissue Specific Requirement for the Inv(16) Oncogene\n                  <i>CBFB::MYH11<\/i>\n                  in Acute Myeloid Leukemia"],"prefix":"10.64898","author":[{"given":"Sipra","family":"Panda","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatasai Rahul","family":"Dogiparthi","sequence":"additional","affiliation":[{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"},{"name":"Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Dhir","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Rivas","sequence":"additional","affiliation":[{"name":"Transgenic Mouse Core, National Human Genome Research Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemlem","family":"Alemu","sequence":"additional","affiliation":[{"name":"Translational and Functional Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Garrett","sequence":"additional","affiliation":[{"name":"Transgenic Mouse Core, National Human Genome Research Institute, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Swenson","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle J.","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"},{"name":"Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Katherine","family":"Hyde","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"1","key":"2026010105425597000_2024.10.06.616896v2.1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41467-017-02376-5","article-title":"Proliferation dynamics of acute myeloid leukaemia and haematopoietic progenitors competing for bone marrow space","volume":"9","year":"2018","journal-title":"Nature communications"},{"key":"2026010105425597000_2024.10.06.616896v2.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-696054"},{"key":"2026010105425597000_2024.10.06.616896v2.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-202606"},{"issue":"2","key":"2026010105425597000_2024.10.06.616896v2.4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","year":"2011","journal-title":"Genes Cancer"},{"key":"2026010105425597000_2024.10.06.616896v2.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc840"},{"key":"2026010105425597000_2024.10.06.616896v2.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400930101"},{"key":"2026010105425597000_2024.10.06.616896v2.7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.141"},{"key":"2026010105425597000_2024.10.06.616896v2.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-688705"},{"key":"2026010105425597000_2024.10.06.616896v2.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2026010105425597000_2024.10.06.616896v2.10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.038976"},{"key":"2026010105425597000_2024.10.06.616896v2.11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.55"},{"key":"2026010105425597000_2024.10.06.616896v2.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401678"},{"key":"2026010105425597000_2024.10.06.616896v2.13","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200107000-00004"},{"key":"2026010105425597000_2024.10.06.616896v2.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.8351518"},{"key":"2026010105425597000_2024.10.06.616896v2.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#"},{"key":"2026010105425597000_2024.10.06.616896v2.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.15.610"},{"key":"2026010105425597000_2024.10.06.616896v2.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06276.x"},{"key":"2026010105425597000_2024.10.06.616896v2.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.12.014"},{"key":"2026010105425597000_2024.10.06.616896v2.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81388-4"},{"key":"2026010105425597000_2024.10.06.616896v2.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.022"},{"key":"2026010105425597000_2024.10.06.616896v2.21","doi-asserted-by":"publisher","DOI":"10.1101\/SQB.1997.062.01.021"},{"key":"2026010105425597000_2024.10.06.616896v2.22","doi-asserted-by":"publisher","DOI":"10.1038\/13776"},{"key":"2026010105425597000_2024.10.06.616896v2.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-434688"},{"key":"2026010105425597000_2024.10.06.616896v2.24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.58"},{"issue":"1","key":"2026010105425597000_2024.10.06.616896v2.25","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/s41598-018-38408-3","article-title":"IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells and promotes cell survival","volume":"9","year":"2019","journal-title":"Scientific Reports"},{"key":"2026010105425597000_2024.10.06.616896v2.26","doi-asserted-by":"crossref","unstructured":"Richter LE , Wang Y , Becker ME , Coburn RA , Williams JT , Amador C , et al. HDAC1 is a Required Cofactor of CBFbeta-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia. Mol Cancer Res. 2019.","DOI":"10.1158\/1541-7786.MCR-18-0922"},{"key":"2026010105425597000_2024.10.06.616896v2.27","doi-asserted-by":"crossref","unstructured":"Mandoli A , Singh AA , Jansen PW , Wierenga AT , Riahi H , Franci G , et al. CBFB-MYH11\/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. Leukemia. 2013.","DOI":"10.1038\/leu.2013.257"},{"key":"2026010105425597000_2024.10.06.616896v2.28","doi-asserted-by":"crossref","unstructured":"Dhir A , Ethell A , Watkins R , Lam C , Tur-Rodriguez K , Persinger J , et al. The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02799-w"},{"issue":"4","key":"2026010105425597000_2024.10.06.616896v2.29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nmeth.4179","article-title":"Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput","volume":"14","year":"2017","journal-title":"Nature methods"},{"key":"2026010105425597000_2024.10.06.616896v2.30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009163"},{"key":"2026010105425597000_2024.10.06.616896v2.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227413"},{"issue":"7","key":"2026010105425597000_2024.10.06.616896v2.32","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41375-023-01926-9","article-title":"Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing","volume":"37","year":"2023","journal-title":"Leukemia"},{"key":"2026010105425597000_2024.10.06.616896v2.33","doi-asserted-by":"crossref","unstructured":"Arnone M , Konantz M , Hanns P , Paczulla Stanger AM , Bertels S , Godavarthy PS , et al. Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity. Cancers (Basel). 2020;12(12).","DOI":"10.3390\/cancers12123742"},{"key":"2026010105425597000_2024.10.06.616896v2.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.08.019"},{"key":"2026010105425597000_2024.10.06.616896v2.35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0601"},{"issue":"1","key":"2026010105425597000_2024.10.06.616896v2.36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41420-024-01823-9","article-title":"Crosstalk between autophagy and metabolism: implications for cell survival in acute myeloid leukemia","volume":"10","year":"2024","journal-title":"Cell Death Discov"},{"issue":"6","key":"2026010105425597000_2024.10.06.616896v2.37","doi-asserted-by":"crossref","first-page":"189214","DOI":"10.1016\/j.bbcan.2024.189214","article-title":"An updated outlook on autophagy mechanism and how it supports acute myeloid leukemia maintenance","volume":"1879","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026010105425597000_2024.10.06.616896v2.38","doi-asserted-by":"crossref","unstructured":"Nepstad I , Hatfield KJ , Gronningsaeter IS , Reikvam H . The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int J Mol Sci. 2020;21(8).","DOI":"10.3390\/ijms21082907"},{"issue":"10","key":"2026010105425597000_2024.10.06.616896v2.39","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3324\/haematol.2023.283757","article-title":"CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children\u2019s Oncology Group","volume":"109","year":"2024","journal-title":"Haematologica"},{"key":"2026010105425597000_2024.10.06.616896v2.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0596-4"},{"issue":"4","key":"2026010105425597000_2024.10.06.616896v2.41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.12640","article-title":"CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML","volume":"14","year":"2020","journal-title":"Mol Oncol"},{"key":"2026010105425597000_2024.10.06.616896v2.42","doi-asserted-by":"crossref","unstructured":"Mou J , Huang Q , Liu X , Liu W , Liu Y , Mei Y , et al. AML1-ETO and CCND2 overexpression cooperate to drive acute myeloid leukemia initiation and progression. J Leukoc Biol. 2025;117(6).","DOI":"10.1093\/jleuko\/qiaf072"},{"key":"2026010105425597000_2024.10.06.616896v2.43","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_25"},{"key":"2026010105425597000_2024.10.06.616896v2.44","doi-asserted-by":"crossref","first-page":"101195","DOI":"10.1016\/j.blre.2024.101195","article-title":"BCL-2 inhibition in haematological malignancies: Clinical application and complications","volume":"65","year":"2024","journal-title":"Blood Rev"},{"key":"2026010105425597000_2024.10.06.616896v2.45","doi-asserted-by":"crossref","unstructured":"Griffioen MS , de Leeuw DC , Janssen J , Smit L . Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers (Basel). 2022;14(14).","DOI":"10.3390\/cancers14143456"},{"issue":"3","key":"2026010105425597000_2024.10.06.616896v2.46","first-page":"1529","article-title":"Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients","volume":"11","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2026010105425597000_2024.10.06.616896v2.47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-022-01262-y","article-title":"The dual role of autophagy in acute myeloid leukemia","volume":"15","year":"2022","journal-title":"Journal of hematology & oncology"},{"key":"2026010105425597000_2024.10.06.616896v2.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2026010105425597000_2024.10.06.616896v2.49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"2026010105425597000_2024.10.06.616896v2.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326843"},{"key":"2026010105425597000_2024.10.06.616896v2.51","doi-asserted-by":"crossref","first-page":"769730","DOI":"10.3389\/fonc.2021.769730","article-title":"Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells","volume":"11","year":"2021","journal-title":"Frontiers in oncology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.10.06.616896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:12:50Z","timestamp":1768461170000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.10.06.616896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2024.10.06.616896","relation":{},"subject":[],"published":{"date-parts":[[2024,10,6]]},"subtype":"preprint"}}